Abbott Q2 2026: sales up 13.0%, adjusted EPS $1.31, guidance raised
Abbott's 13.0% reported sales growth is mostly the Exact Sciences deal, not the base business — comparable growth was 4.8%. Adjusted EPS of $1.31 squeaked past the $1.2922 consensus, and management raised the full-year adjusted EPS range to $5.45–$5.60. The catch: getting from 4.8% to the guided 6.5%–7.5% comparable growth needs a much stronger second half.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS fell to $0.53 from $1.01, while adjusted EPS rose 4.0% to $1.31 from $1.26 and beat the $1.2922 consensus by a hair. The $0.78-per-share gap is specified items: $658 million of intangible amortization plus other net expenses of $519 million, including $385 million for legal reserves tied to an agreed-in-principle settlement. Net income of $928 million was down 47.8% year over year.
Revenue was $12.59 billion, up 13.0% from $11.14 billion a year earlier, but only 4.8% of that was comparable growth; the rest is largely the Exact Sciences acquisition, which closed on March 23, 2026. Diagnostics reported a 42.3% jump while comparable Diagnostics growth was just 2.9%. Nutrition was the weak spot, down 3.1% on a reported basis and 3.6% comparable.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.